Advertisement

Topics

AstraZeneca’s Lynparza shows positive outcome in Phase III trial for ovarian cancer

19:00 EDT 4 Jun 2017 | Net Resources International

AstraZeneca has reported positive findings from the Phase III SOLO-2 clinical trial of Lynparza (olaparib) to treat patients with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer.

Original Article: AstraZeneca’s Lynparza shows positive outcome in Phase III trial for ovarian cancer

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca’s Lynparza shows positive outcome in Phase III trial for ovarian cancer"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...